Supernus Pharmaceuticals Q2 EPS $(0.02) Beats $(0.23) Estimate, Sales $135.56M Miss $144.38M Estimate
Portfolio Pulse from totan@benzinga.com
Supernus Pharmaceuticals reported Q2 earnings per share (EPS) of $(0.02), beating the analyst consensus estimate of $(0.23) by 91.3%. However, the company's quarterly sales of $135.56 million missed the analyst consensus estimate of $144.38 million by 6.11%. This represents a 114.29% decrease in EPS and a 20.28% decrease in sales compared to the same period last year.
August 08, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Supernus Pharmaceuticals' Q2 results showed a significant beat on EPS but a miss on sales. This mixed performance could lead to uncertainty in the market.
While the company's EPS beat estimates, which is a positive sign, the miss on sales could be a concern for investors. This mixed performance could lead to uncertainty about the company's future performance, potentially impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100